STK11 and cancer: STK11 WT-mKEAP1 and STK11 WT-KEAP1 WT were more prevalent in patients with KRAS WT cancer, than those with KRAS G12C-positive cancer (15.0% vs 8.1%; p = 0.01 and 65.9% vs 53.4%, p = 0.02, respectively) (Table 1).